BusinessPeregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2017 and Recent DevelopmentsBy Nasdaq OMXSep 8, 2016, 8:05 PM UTC
BusinessNational Comprehensive Cancer Network (NCCN) Awards Three Grants for Combination Studies of Peregrine Pharmaceuticals’ Bavituximab in Multiple CancersBy Nasdaq OMXSep 6, 2016, 12:45 PM UTC
BusinessPeregrine to Report Financial Results for First Quarter of Fiscal Year 2017 After Market Close on September 8, 2016By Nasdaq OMXSep 1, 2016, 8:05 PM UTC
BusinessAvid Bioservices to Participate in Cambridge Healthtech Institute’s (CHI) 8th Annual The Bioprocessing SummitBy Nasdaq OMXAug 9, 2016, 12:05 PM UTC
BusinessPreclinical Data Presented at American Association for Cancer Research (AACR) Annual Meeting Demonstrate Enhanced Therapeutic Benefit of Combining a PS-Targeting Antibody With Anti-PD-1 Therapy in Models of Triple Negative Breast Cancer (TNBC)By Nasdaq OMXApr 20, 2016, 12:05 PM UTC
BusinessPeregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred StockBy Nasdaq OMXMar 7, 2016, 9:05 PM UTC
BusinessPeregrine to Report Financial Results for Third Quarter of Fiscal Year 2016 Prior to Market Open on March 9, 2016By Nasdaq OMXMar 3, 2016, 9:05 PM UTC
BusinessPeregrine Pharmaceuticals Provides Update on Phase III SUNRISE Trial of BavituximabBy Nasdaq OMXFeb 25, 2016, 9:05 PM UTC
